As of 2026-03-18, the EV/EBITDA ratio of Jounce Therapeutics Inc (JNCE) is 1.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. JNCE's latest enterprise value is -51.62 mil USD. JNCE's TTM EBITDA according to its financial statements is -48.70 mil USD. Dividing these 2 quantities gives us the above JNCE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.6x - 16.3x | 14.6x |
| Forward P/E multiples | 15.5x - 21.8x | 18.6x |
| Fair Price | (11.52) - (12.22) | (12.47) |
| Upside | -712.6% - -750.0% | -763.5% |
| Date | EV/EBITDA |